稳定性性结肠炎患者的infliximab组织度与更持久的infliximab相关疾病缓解相关
John Choi1, Qian Wang2, Melanie Beaton3
1Department of Physiology and Pharmacology, Western University, Medical Sciences Building, Rm 216, London, ON, N6A 5C1, Canada.
在性结肠炎 (UC) 中,组织内因弗利克西马布水平,而不是血水平,预测疾病复发. 在非炎症组织中使用Infliximab的较高水平可能会改善治疗的耐久性.
科学领域:
- 胃肠病学 胃肠病学
- 临床药理学 临床药理学
- 免疫学 免疫学 免疫学
背景情况:
- 性结肠炎 (UC) 的管理包括INFLIXIMAB治疗.
- 了解infliximab的组织与血度对于治疗优化至关重要.
- 需要评估infliximab水平,疾病活性和UC患者的长期结果之间的关系.
研究的目的:
- 为了将组织和血中的Infliximab度与UC门诊患者的组织学疾病活性相关联.
- 调查因弗利克西马布水平与长期临床结果之间的关系.
- 评估组织内因弗利克西马布度的参与者内变异性和与瘤缩因子-α (TNF-α) 的相关性.
主要方法:
- 对接受infliximab的UC患者进行前性队列研究.
- 收集血液和西格结肠活检,用于因弗利西马布和TNF-α量化.
- 评估了组织学疾病活性,并对患者进行了2年的临床结果跟踪.
主要成果:
- 平均血和非炎症组织内因弗力西马布度之间的正相关性 (Rs=0.75,P=.0071).
- 较低的平均组织infliximab与较短的疾病复发时间相关 (Rs=0.77,P=.032),与血水平不同.
- 在infliximab度中没有显著的参与者内部变异;TNF-α和疾病活性之间没有相关性.
结论:
- 血infliximab反映了UC患者的组织暴露缓解,但不是那些有活跃疾病的患者.
- 在非炎症组织中的Infliximab度较高可能会提高Infliximab的耐用性.
- 无论是血还是组织TNF-α都与UC疾病活性无关,这需要进一步研究.
更多相关视频
07:05Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
Published on: December 15, 2017
11:09An HS-MRM Assay for the Quantification of Host-cell Proteins in Protein Biopharmaceuticals by Liquid Chromatography Ion Mobility QTOF Mass Spectrometry
Published on: April 17, 2018
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
